Fibrobiologics Inc (FBLG) FinancialsFBLGFinancialFibrobiologics Inc

Evaluating the bottom line, Fibrobiologics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -660.08%, provide a clear picture of how effectively FBLG converts its operational activities into shareholder value.

In the context of the broader market, FBLG competes directly with industry leaders such as BON and TRAW. With a market capitalization of $9.92M, it holds a leading position in the sector. When comparing efficiency, FBLG's gross margin of N/A stands against BON's 24.00% and TRAW's N/A. Such benchmarking helps identify whether Fibrobiologics Inc is trading at a premium or discount relative to its financial performance.

Fibrobiologics has reported consistent net income losses, totaling -5 million USD in Q1 2026, and a negative EPS of -0.66 for the last quarter. The company's debt to equity ratio has fluctuated significantly, indicating financial instability.